Alzheimer’s Drug Researchers with ADDF Grants Gaining Access to New Services

Alzheimer’s Drug Researchers with ADDF Grants Gaining Access to New Services
PsychoGenics Inc. and the Alzheimer's Drug Discovery Foundation (ADDF) announced a collaboration that opens PsychoGenics’ Alzheimer’s animal models and investigational services to recipients of ADDF grants who are working in preclinical Alzheimer’s drug discovery programs. Through the collabortion, PsychoGenics will offer its products and services to ADDF-funded biotechnology companies on "extremely favorable financial terms" through risk-sharing agreements, which has the effect of increasing an ADDF grant's value. "We are delighted to collaborate with PsychoGenics to make its expertise and services available to our Alzheimer's research community. This beneficial partnership will allow our critical funding to go further. Together, we will accelerate preclinical drug discovery programs in our portfolio and move closer to our goal of developing new treatments for Alzheimer's disease," Dr. Howard Fillit,  ADDF’s executive director and CSO, said in a press release. PsychoGenics, founded in 1999, specializes in in vivo phenotypic drug discovery. Its proprietary technology platforms are used in partnership with pharmaceutical and biotechnology companies to advance drug discovery for central nervous system (CNS) disorders. The company offers a variety of behavioral tests and in-licensed transgenic mouse models, including those pertinent to Alzheimer's research. ADDF-funded researchers will have access to PsychoGenics’ services that include:

Leave a Comment

Your email address will not be published. Required fields are marked *